DK1863519T3 - Modulering af hgf/hgfr-aktivitet til behandling af lymfødem - Google Patents

Modulering af hgf/hgfr-aktivitet til behandling af lymfødem

Info

Publication number
DK1863519T3
DK1863519T3 DK06749190.2T DK06749190T DK1863519T3 DK 1863519 T3 DK1863519 T3 DK 1863519T3 DK 06749190 T DK06749190 T DK 06749190T DK 1863519 T3 DK1863519 T3 DK 1863519T3
Authority
DK
Denmark
Prior art keywords
hgf
modulation
hgfr activity
treat lymphedema
lymphedema
Prior art date
Application number
DK06749190.2T
Other languages
Danish (da)
English (en)
Inventor
Michael Detmar
Kentaro Kajiya
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of DK1863519T3 publication Critical patent/DK1863519T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
DK06749190.2T 2005-03-31 2006-03-30 Modulering af hgf/hgfr-aktivitet til behandling af lymfødem DK1863519T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66746305P 2005-03-31 2005-03-31
PCT/US2006/012389 WO2006105511A1 (en) 2005-03-31 2006-03-30 Monitoring and modulating hgf/hgfr activity

Publications (1)

Publication Number Publication Date
DK1863519T3 true DK1863519T3 (da) 2014-01-13

Family

ID=36638370

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06749190.2T DK1863519T3 (da) 2005-03-31 2006-03-30 Modulering af hgf/hgfr-aktivitet til behandling af lymfødem

Country Status (10)

Country Link
US (4) US20070010443A1 (enExample)
EP (2) EP2674165B1 (enExample)
JP (5) JP5313660B2 (enExample)
KR (3) KR20070119710A (enExample)
CN (2) CN101189023B (enExample)
DK (1) DK1863519T3 (enExample)
ES (1) ES2440953T3 (enExample)
PL (1) PL1863519T3 (enExample)
TW (1) TWI362940B (enExample)
WO (1) WO2006105511A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
JP4171061B2 (ja) 2005-02-09 2008-10-22 アーキュール，インコーポレーテッド マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
JP5313660B2 (ja) * 2005-03-31 2013-10-09 ザ ジェネラル ホスピタル コーポレイション Ｈｇｆ／ｈｇｆｒ活性の観察と調節
WO2007013603A1 (ja) 2005-07-28 2007-02-01 Anges Mg, Inc. リンパ管新生促進剤
US20090169473A1 (en) * 2005-10-24 2009-07-02 Fujifilm Ri Pharma Co., Ltd. Diagnostic agent and therapeutic agent for disease associated with hepatocyte growth factor receptor
EP2173748B1 (en) 2007-06-22 2011-08-31 ArQule, Inc. Indolyl pyrrolidines for the treatment of cancer
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
JP2010530885A (ja) 2007-06-22 2010-09-16 アークル インコーポレイテッド キナゾリノン化合物およびその使用方法
EP2236605B1 (en) * 2007-12-28 2016-06-08 The Chemo-Sero-Therapeutic Research Institute Human anti-alpha 9 integrin antibody
CN102869776B (zh) * 2009-12-23 2017-06-23 库尔纳公司 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
WO2016149265A1 (en) 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof
KR101843248B1 (ko) * 2015-03-17 2018-03-29 고려대학교 세종산학협력단 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물
US10344071B2 (en) 2015-07-28 2019-07-09 Musc Foundation For Research Development Identification of novel anti-fibrotic peptide in C-terminal region of the MET receptor tyrosine kinase
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用
CN114292899B (zh) * 2022-01-08 2024-03-26 安徽医科大学第一附属医院 一种肝细胞生长因子检测及信号增敏探针、引物对及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4683196A (en) 1983-12-12 1987-07-28 Meru, Inc. Method and materials for the identification of lipopolysaccharide producing microorganisms
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5573933A (en) 1987-04-14 1996-11-12 Luminis Pty, Ltd. Transgenic pigs
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
JP2650159B2 (ja) 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー 核酸増幅方法
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US6013431A (en) 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5922854A (en) 1991-06-14 1999-07-13 Kumar; Ramesh Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5316921A (en) 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
WO1993025071A1 (en) 1992-06-12 1993-12-23 Dnx Corporation Production of human hemoglobin in transgenic pigs
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0662130B1 (en) 1992-09-18 1997-11-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A method of producing hepatocyte growth factor and a cell line
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
US5714320A (en) 1993-04-15 1998-02-03 University Of Rochester Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE247716T1 (de) 1994-02-07 2003-09-15 Beckman Coulter Inc Ligase/polymerase-vermittelte analyse genetischer elemente von einzelnukleotid-polymorphismen und ihre verwendung in der genetischen analyse
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6143495A (en) 1995-11-21 2000-11-07 Yale University Unimolecular segment amplification and sequencing
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
WO1997035033A1 (en) 1996-03-19 1997-09-25 Molecular Tool, Inc. Method for determining the nucleotide sequence of a polynucleotide
DE69739856D1 (de) 1996-07-03 2010-06-02 Genentech Inc Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen
GB9618050D0 (en) 1996-08-29 1996-10-09 Cancer Res Campaign Tech Global amplification of nucleic acids
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
JP4642303B2 (ja) * 1999-09-21 2011-03-02 アンジェスＭｇ株式会社 脳血管障害のための遺伝子治療
EP1242451A2 (en) * 1999-12-15 2002-09-25 EntreMed, Inc. Compositions and methods for inhibiting endothelial cell proliferation
US20020102260A1 (en) * 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
WO2001083819A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
WO2002029087A2 (en) 2000-10-02 2002-04-11 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
CN1150035C (zh) * 2000-12-21 2004-05-19 中国人民解放军军事医学科学院放射医学研究所 一种重组质粒及其在疾病防治中的应用
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7556944B2 (en) 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
ATE435303T1 (de) 2002-08-12 2009-07-15 New England Biolabs Inc Verfahren und zusammensetzungen in verbindung mit gen-silencing
DE10242663A1 (de) * 2002-09-13 2004-03-25 Forschungszentrum Karlsruhe Gmbh Verfahren zur Identifizierung von Inhibitoren in vivo
US20050026830A1 (en) * 2003-05-14 2005-02-03 Yasushi Kawaguchi Compositions and methods for treating fibrosis
WO2005023287A1 (ja) * 2003-09-03 2005-03-17 Kringle Pharma Inc. ヒト組換えｈｇｆを含有する皮膚潰瘍予防治癒剤
DE602005021272D1 (de) * 2004-03-31 2010-07-01 Anges Mg Inc Gentherapie mit Hepatozyten-Wachstumsfaktor zur Verbesserung des Überlebens von Muskel- und Hautgewebelappen
JP5313660B2 (ja) * 2005-03-31 2013-10-09 ザ ジェネラル ホスピタル コーポレイション Ｈｇｆ／ｈｇｆｒ活性の観察と調節
JP4111993B2 (ja) * 2006-05-29 2008-07-02 アンジェスＭｇ株式会社 リンパ管新生促進剤
JP2016031772A (ja) 2014-07-30 2016-03-07 株式会社日立ハイテクファインシステムズ 熱アシスト磁気ヘッド素子の検査方法及びその装置

Also Published As

Publication number Publication date
US20070010443A1 (en) 2007-01-11
KR20070119710A (ko) 2007-12-20
PL1863519T3 (pl) 2014-03-31
TW200722099A (en) 2007-06-16
US20150030611A1 (en) 2015-01-29
JP4664441B2 (ja) 2011-04-06
US20100227821A1 (en) 2010-09-09
CN101189023B (zh) 2013-01-30
CN102989012B (zh) 2015-05-13
EP2674165A2 (en) 2013-12-18
JP5313660B2 (ja) 2013-10-09
CN102989012A (zh) 2013-03-27
JP2008538551A (ja) 2008-10-30
JP5722960B2 (ja) 2015-05-27
TWI362940B (en) 2012-05-01
JP2012149087A (ja) 2012-08-09
US8865673B2 (en) 2014-10-21
EP1863519B1 (en) 2013-09-25
US20130064833A1 (en) 2013-03-14
JP2010265266A (ja) 2010-11-25
HK1183441A1 (en) 2013-12-27
ES2440953T3 (es) 2014-01-31
JP2013216690A (ja) 2013-10-24
EP2674165A3 (en) 2014-07-30
KR20130114763A (ko) 2013-10-18
JP2013136622A (ja) 2013-07-11
EP2674165B1 (en) 2016-10-12
KR20140068234A (ko) 2014-06-05
CN101189023A (zh) 2008-05-28
EP1863519A1 (en) 2007-12-12
WO2006105511A1 (en) 2006-10-05
JP5801835B2 (ja) 2015-10-28

Similar Documents

Publication Publication Date Title
DK1863519T3 (da) Modulering af hgf/hgfr-aktivitet til behandling af lymfødem
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK1720866T3 (da) Fremgangsmåde
BRPI0817775A2 (pt) Métodos de tratar distúrbios urogenitais-neurológicos usando toxinas clostridiais modificadas
DK1874821T3 (da) Kombination af antistoffer med glykokortikoider til behandling af kræft
HUS1600054I1 (hu) Terápiás szerek farmakokinetikai paramétereinek modulálása
EP2175873A4 (en) TREATMENT AGAINST ANXIETY
DK1827441T3 (da) Kombinationer til behandling af sygdomme, som involverer celleproliferation
IL189976A0 (en) Methods of modulating neurotrophin-mediated activity
BRPI0816994A2 (pt) Derivado uracila ou timina para tratar hepatite c
DE602005012267D1 (de) N von geräten
DE602006013070D1 (de) Frequenzerweiterung von harmonischen Signalen
DK1942938T3 (da) Anvendelse af oligouronater til behandling af slim-hyperviskositet
EP2040730A4 (en) MODULATION OF NKG2D
DE602006004463D1 (de) Kristallform von asenapinmaleat
DE502007002264D1 (de) Substituierte arylsulfonamide als antivirale mittel
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
EP1893463A4 (en) ESTIMATING INTERACTION FORCES BETWEEN WHEELS AND RAIL
DE112008002473A5 (de) Bestimmung der Aktivität von Proteasen
DK1863899T3 (da) Hudbehandlingspræparater
PL2162238T3 (pl) Obróbka powierzchni termicznie modyfikowanego drewna
BRPI0613661A2 (pt) centro de atividade
DE502006004941D1 (de) Von hohlprofilen
ATE483460T1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken